Vertex Price Cash Flow Ratio from 2010 to 2024

VRTX Stock  USD 465.73  2.40  0.51%   
Vertex Pharmaceuticals Price Cash Flow Ratio yearly trend continues to be fairly stable with very little volatility. Price Cash Flow Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Vertex Pharmaceuticals Price Cash Flow Ratio regression line of annual values had r-squared of  0.12 and arithmetic mean of (7.72). View All Fundamentals
 
Price Cash Flow Ratio  
First Reported
2010-12-31
Previous Quarter
29.64282164
Current Value
31.12
Quarterly Volatility
97.15980765
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Price Cash Flow Ratio Growth Pattern

Below is the plot of the Price Cash Flow Ratio of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' Price Cash Flow Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Price Cash Flow Ratio10 Years Trend
Slightly volatile
   Price Cash Flow Ratio   
       Timeline  

Vertex Price Cash Flow Ratio Regression Statistics

Arithmetic Mean(7.72)
Geometric Mean42.46
Coefficient Of Variation(1,259)
Mean Deviation63.13
Median29.64
Standard Deviation97.16
Sample Variance9,440
Range400
R-Value0.35
Mean Square Error8,916
R-Squared0.12
Significance0.20
Slope7.62
Total Sum of Squares132,160

Vertex Price Cash Flow Ratio History

2024 31.12
2023 29.64
2022 17.91
2021 21.41
2020 18.88
2019 35.82
2018 33.17

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Price Cash Flow Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Cash Flow Ratio 29.64  31.12 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.